Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, monlunabant
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results,
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Nordisk’s obesity newcomer monlunabant heads into Phase IIb
Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
Friday, shares of Novo Nordisk A/S (NVO) are sliding following the announcement of safety results of phase 2a clinical trial of
STAT
12h
Novo’s new obesity drug shows modest results, raises concerns of psychiatric side effects
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
FierceBiotech
12h
Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
4h
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
10h
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
STAT
1d
Corbus sees Novo’s controversial obesity approach as a ticket to a blockbuster
Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.
2d
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ...
14h
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback